Dr Haakon Ragde Biopgraphy. Call in show to night at 6PM-7PM Pacific Time

[Guest guest]

Call in show: 6PM-7PM Pacific time tonightCall in -1-Internet access to live audio stream: www.pcref.org/showSan Diego area Radio KCEO AM 1000

Happy Listening Exciting subject : Cryo-Immuno-Therapy

Haakon Ragde, M.D.

Curriculum Vitae

Dr.

Ragde, a Board Certified urologist, was born in Norway

and immigrated to the United

States in 1948. He served in the Korean War as a forward artillery

observer with the 2nd US Infantry Division, for which he was awarded

the Silver Star, the Bronze Star with V and Oak Leaf Cluster, and the Purple

Heart. Following his service, he entered

the University of

Virginia, where he

graduated with an M.D. degree in 1957.

Dr.

Ragde trained at McGill University in Montreal,

Canada; Sloan-Kettering

Cancer Center, New

York; Cleveland Clinic, Cleveland;

and University of Washington, Seattle,

where he completed a fellowship in immuno-oncology.

In

1965, Dr. Ragde, as a member of a two-man team, performed the first successful kidney

transplants in the State of Washington.

Between 1965 and 1970 he was a member of a four-man physician team that

developed bone marrow transplantation.

The chief of the team, Dr. E. Donnall was awarded the 1990 Nobel

Prize in medicine.

Dr. Ragde developed:

Transrectal

ultrasound into a mainstay of the clinical practice of urology;The

currently used transrectal ultrasound-guided biopsy method;Transrectal

ultrasound-guided prostate brachytherapy (currently, 55% of newly

diagnosed men with prostate cancer in the U.S. select this treatment)

Dr. Ragde

established:

Pacific

Northwest Cancer Foundation, from which Northwest Biotherapeutics, Inc., a

biotechnology company specializing in immunotherapy, arose in 1996; he

served as a director until June, 2004;In 2002

he established The Haakon Ragde Foundation for Advanced Cancer Studies,

for which he donates his time as Chairman and Executive Director.

Dr.

Ragde holds two professorships in Urology: one at the University

of Virginia, his alma mater, and the

other at the University

of Washington. In 1997 he was elected to Honorary Membership

in the International Union Against Cancer.

In 2000 he was elected to the Willet Whitmore Society, Sloan-Kettering Cancer Center, New

York. He is an

author of over 100 scientific papers, several textbook chapters, and has been

an invited speaker to major universities and societies world-wide.

Dr.

Ragde retired from clinical practice in 2003, but remains active in the

research of novel methods of treating advanced cancer through his

foundation. Currently, he is involved in

studying a treatment for advanced, recurrent prostate cancer known as

"dendritic cell-based cryoimmunotherapy".

This "active immunotherapeutic" concept involves the cryo-destruction of

a targeted tumor, followed by the introduction of millions of dendritic cells

into the site of the cryo-destroyed malignancy.

The

dendritic cell is known as a "professional" antigen presenting cell, and excels

at the uptake of "antigen", or protein, in this case associated with

cancer. By doing so, the dendritic cell

is potentially capable of stimulating an immune response against the cancer

systemically. Along with the stimulatory

portion of the treatment, an additional step – known as "selective T cell

depletion" – is taken to counter the part of the immunity that has tolerated

the cancer, or allowed it to progress under the auspices of the immune

system.

Study

of this technology is currently ongoing overseas. It is hoped that a U.S. clinical trial program will

begin in the next 12 months.

-- Material posted here is for general education purposes only and does not take the place of medical advice from your treating physician. No patient-doctor relationship is created or implied.

Israel Barken, M.D. Medical Director Prostate Cancer Research and Eduction Foundation (PC-REF) 501©3 non profit organization 5480 Baltimore Drive, #202La Mesa, Ca. 91942

www.pcref.orginfo@...